Green Tomato
3
178M
1
0.14
0.67
1
- Areas of investment
Summary
The standard case for the fund is to invest in rounds with 4 partakers. Despite the Green Tomato, startups are often financed by ShenZhen GTJA Investment Group, Shanghai Fosun Pharmaceutical (Group) Co.,Ltd, Joyful Ascent. The meaningful sponsors for the fund in investment in the same round are ShenZhen GTJA Investment Group, Shanghai Fosun Pharmaceutical (Group) Co.,Ltd, New China Capital Management. In the next rounds fund is usually obtained by New China Capital Management, Loyal Valley Capital, CICC.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Shanghai Henlius. Among the most successful fund investment fields, there are Health Care, Medical.
The average startup value when the investment from Green Tomato is more than 1 billion dollars. The usual things for fund are deals in the range of more than 100 millions dollars. The fund is generally included in less than 2 deals every year. The top activity for fund was in 2017.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 0
- Exits
- 1
- Rounds per year
- 0.14
- Follow on index
- 0.67
- Investments by industry
- Biotechnology (3)
- Medical (3)
- Health Care (3)
- Pharmaceutical (3)
- Investments by region
-
- China (3)
- Peak activity year
- 2017
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 15
- Avg. valuation at time of investment
- 2B
- Group Appearance index
- 1.00
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Shanghai Henlius Biotech | 22 Dec 2017 | Biotechnology, Health Care, Medical, Pharmaceutical | Early Stage Venture | 190M | Shanghai, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.